SHANGHAI, March 12, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held in San Diego, USA, from April 5-10, 2024.
The AACR Annual Meeting is one of the largest cancer research conferences in the world. The abstracts have been published on the AACR official website.
Poster Presentation
01 Abstract title: Disrupting IL-11/IL-11R signaling by an efficacious anti-IL-11 antibody 9MW3811 enhances T cell tumor infiltration and synergizes with anti-PD-1 therapies in vivo Abstract Number: 2365 Location: Poster Section 38 Poster Board Number: 11 Session Date and Time: Apr 8, 20249:00 AM - 12:30 PM PDT
02 Abstract title: 2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys Abstract Number: 6349 Location: Poster Section 41 Poster Board Number: 10 Session Date and Time: Apr 9, 20241:30 PM - 5:00 PM PDT
03 Abstract title: 2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells Abstract Number: 6350 Location: Poster Section 41 Poster Board Number: 10 Session Date and Time: Apr 9, 2024 1:30 PM - 5:00 PM PDT
About 9MW3811
9MW3811 is a high-affinity humanized neutralizing antibody against IL-11. It is currently undergoing Phase 1 clinical trials in Australia and China. IL-11 is an important inflammation factor that plays a crucial role in fibrosis and the development and progression of tumors. Studies have shown that high expression of IL-11 is associated with the prognosis of various tumors such as lung cancer, liver cancer, and colorectal cancer. It has significant effects on various cells in the tumor microenvironment, including tumor cells, macrophages, T cells, and tumor-associated fibroblasts. 9MW3811 inhibits the activation of the downstream signaling pathway of IL-11 by blocking the binding of IL-11 to IL-11R, demonstrating good anti-tumor therapeutic effects in multiple preclinical pharmacodynamic models. When used in combination with anti-PD-1 antibodies, 9MW3811 significantly promotes the infiltration of CD8+ T lymphocytes, improving the T cell exhaustion caused by anti-PD-1 antibodies, thereby showing better combined anti-tumor efficacy.
About 2MW4991
2MW4991 is a high-specificity, high-affinity ADCC-enhanced antibody targeting integrin αvβ8. Integrin αvβ8 is an important activator of TGF-β, specifically regulating the activity of TGF-β in immune cells. Studies have found that integrin αvβ8 is highly expressed in certain tumors, and blocking αvβ8 can completely inhibit the release of TGF-β. 2MW4991 exhibits strong anti-tumor activity in immune-excluded tumor models, significantly promoting immune cell infiltration in immune-excluded tumors and greatly increasing the sensitivity of immune-excluded tumors to PD1 inhibitors.
About 2MW4691
2MW4691 is an ADCC-enhanced bispecific antibody targeting CCR8/CTLA-4. CTLA-4 is expressed on both CD8+ T cells and Tregs, and targeting CTLA-4 has a strong anti-tumor effect, but its clinical application is limited due to strong side effects. CCR8 is a specific marker for tumor infiltrating Tregs, almost not expressed on other immune cells and peripheral Tregs. 2MW4691 retains high affinity for CCR8 and attenuated CTLA-4 targeting activity, specifically eliminating tumor-infiltrating Tregs and blocking the immunosuppression mediated by CTLA-4 signaling on peripheral CD8+ T cells. It demonstrates strong anti-tumor activity in preclinical transgenic animal models and shows good safety in primates.
About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, auto-immune diseases, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 2 products have been approved and commercialized, 2 products have been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality". For more information, please visit www.mabwell.com/en.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.
